CLDX
Celldex Therapeutics Inc
31.10$
-1.2%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | – | 100.0% | 100.0% | 100.0% | 100.0% | |
| 50.6% | 736.5% | 496.8% | 31.9% | 1,418.5% | 69.7% | 7,570.4% | 7,424.1% | – | – | 5,693.3% | – | – | |
| 49.4% | -636.5% | -396.8% | 68.1% | -1,318.5% | 30.3% | -7,470.4% | -7,324.1% | – | 100.0% | -5,593.3% | 100.0% | -56,850.9% | |
| 2,276.5% | 736.5% | 19,798.7% | 1,556.8% | 1,418.5% | 3,925.1% | 7,570.4% | 7,424.1% | – | 100,478.7% | 486,673.3% | 307,040.9% | 248,964.3% | |
| 541.9% | 213.8% | 5,835.3% | 365.4% | 315.1% | 873.4% | 1,556.8% | 1,423.4% | – | 15,870.7% | 76,326.7% | 59,559.1% | 42,090.2% | |
| 2,767.9% | 516.4% | 25,634.0% | 1,922.3% | 315.1% | 4,798.6% | 1,556.8% | 1,423.4% | – | 116,349.3% | 557,306.7% | 366,568.2% | 234,097.3% | |
| -2,718.5% | -1,152.9% | -26,030.8% | -1,854.2% | -1,633.5% | -4,768.3% | -9,027.2% | -8,747.5% | – | -116,249.3% | -562,900.0% | -366,468.2% | -290,948.2% | |
| – | 75.3% | – | – | – | – | – | – | – | – | – | – | – | |
| -2,522.1% | -1,048.3% | -21,030.8% | -1,434.8% | -1,320.0% | -4,007.8% | -7,740.4% | -7,753.4% | – | -108,480.0% | -524,566.7% | -334,104.5% | -268,385.7% | |
| -196.4% | 324.0% | 469.1% | – | – | – | – | – | – | – | – | – | – | |
| -2,522.1% | -1,048.3% | -21,030.8% | -1,434.8% | -1,320.0% | -4,007.8% | -7,740.4% | -7,753.4% | – | -108,480.0% | -524,566.7% | -334,104.5% | -268,385.7% | |
| -2,471.5% | -832.0% | -20,534.0% | -1,402.9% | -1,295.4% | -3,938.1% | -7,615.7% | -7,633.8% | – | -107,392.0% | -518,873.3% | -330,004.5% | -265,353.6% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.